• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2018

View Archived Issues

Aging microbiome triggers immunity changes, insulin resistance

Read More

Leo Pharma and PellePharm collaborate to advance innovative therapies for rare skin diseases

Read More

Variations of variations could give new insights into AD, brain organization

Read More

Medivir nominates MIV-828 as candidate drug for AML and hematological malignancies

Read More

Zenith Epigenetics announces collaboration with Pfizer in breast cancer clinical trial

Read More

A next-generation cyclin-dependent kinase inhibitor from Pfizer presented

Read More

YHO-1701 demonstrates promising in vivo activity as monotherapy or in combinations

Read More

Novel bioactive lipid nanoparticle demonstrates efficacy in multiple human tumor models

Read More

Synthetic announces successful completion of end-of-phase II meeting with FDA regarding ribaxamase

Read More

EVT-601, a first-in-class allosteric FGFR antagonist

Read More

Novartis AG patents new DNA gyrase inhibitors as antibacterials

Read More

FDA grants accelerated approval to Venclexta for newly diagnosed AML

Read More

Axxam SpA presents P2X7 receptor antagonists

Read More

FDA approves Daurismo for newly diagnosed AML ineligible for intensive chemotherapy

Read More

Discovery and characterization of novel potent and selective CD73 inhibitor A-001202

Read More

MDM2 degraders for anticancer therapy presented

Read More

IBT amends planned phase III protocol for IBP-9414

Read More

Final phase I/Ib study results with Pulmazole support advancement to phase II

Read More

AU-15506, a highly potent, selective inhibitor of CDK12 with oral efficacy in a TNBC model

Read More

GlaxoSmithKline begins first-in-human study of GSK-3368715 in solid tumors and DLBCL

Read More

New phase II/III study in Hong Kong investigates JCM-16021 for diarrhea-predominant IBS

Read More

REALIST study explores use of mesenchymal stem cells to treat ARDS

Read More

Arcus presents novel small-molecule CD73 inhibitors for orally bioavailable cancer therapy

Read More

Phase I results demonstrate encouraging efficacy for D2C7-IT in malignant glioma

Read More

HitGen and Biogen form drug discovery research collaboration

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe